Pertussis is a highly contagious disease, for which periodic peaks in incidence and an
increasing number of outbreaks have been observed over the last decades. The reduced …

A tricomponent acellular pertussis vaccine containing pertussis toxoid, filamentous
hemagglutinin, and pertactin combined with diphtheria and tetanus toxoids (DTPa) was …

Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

Many countries including Japan have adapted acellular pertussis vaccines combined with
diphtheria and tetanus toxoids (DTaP). DTaP vaccine coverage is approximately> 90%, but …

This Policy Statement was retired January 2015. The American Academy of Pediatrics and
the Centers for Disease Control and Prevention are amending previous recommendations …

A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of
a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison …

The aim of this assessor-blinded trial was to compare the immunogenicity and reactogenicity
of a candidate diphtheria, tetanus toxoids and acellular pertussis vaccine with reduced …

During spring 2005, two tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
vaccine (Tdap) products formulated for use in adolescents (and, for one product, use in …

A new generation of recombinant acellular pertussis vaccine containing genetically
inactivated pertussis toxin (PTgen) was licensed as a monovalent pertussis vaccine (aP gen; …

Background This study assessed the safety and immunogenicity of a new booster vaccine
against tetanus, diphtheria, and pertussis manufactured by Serum Institute of India Pvt. Ltd …